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1,25(OH)2D3 receptors and endorgan response in experimental
aluminium intoxication. Severe aluminium—induced osteomalacia is
refractory to treatment with I ,25(OH)2D3 which frequently causes
hypercalcemia. To further explore the mechanisms involved, we have
utilized a model of short—term aluminium intoxication in the rat (total:
11 mg elemental aluminium in 3 weeks) to study (a) 1 ,25(OH)2D3
receptor status in a variety of classical and non-classical target organs
for I ,25(OH)2D3; (b) circulating 1 ,25(OH)2D3 levels; (C) baseline duo-
denal calcium transport, utilising the Ussing chamber, to investigate the
functional significance of receptor status in a classical target organ; and
(d) duodenal calcium transport response to exogenously administered
1 ,25(OH)2D3. Both in the three week model and in the 16 week model
(total: 41 mg elemental calcium) increased maximal specific binding
capacity for I ,25(OH)2D3 (Nma,j, that is, number of unoccupied recep-
tors, was observed in nuclear fractions of all tissues studied. Receptor
affinity, the apparent dissociation constant K, was unchanged. Total
binding capacity, measured after displacement of endogenous ligand by
Mersalyl, that is, the sum of occupied plus non-occupied receptors, was
also increased. Both circulating I ,25(OH)2D3, mucosa—to—serosa cal-
cium flux (Jms) and net calcium flux (Jnet) were reduced under baseline
conditions, suggesting the lack of a direct relationship between receptor
expression and endorgan response. Following exogenous I ,25(OH)2D3
administration, calcium Jms and met were significantly lower in the
aluminium intoxicated animals, with the increment induced in Jnet in
aluminium intoxicated animals being 63% of that induced in controls.
Our data suggest that resistance to the action of 1,25(OH)2D3 in
aluminium intoxication is postreceptor in nature.
Aluminium intoxication in patients undergoing hemodialysis
may cause severe osteomalacia [1—31, refractory to treatment
with vitamin D or its metabolites. The present study was
designed to address the question whether alterations in
1 ,25(OH)2D3 receptor status and/or endorgan responsiveness to
1 ,25(OH)2D3 might be implicated in its pathogenesis and resist-
ance to treatment.
In aluminium intoxication, circulating I ,25(OH)2D3 concen-
trations are low [4]. In order to exclude that diminished
occupancy of receptor by endogenous ligand was responsible
for apparent reduction of maximal specific—binding capacity,
experiments were carried out to measure total binding capacity,
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that is, the sum of occupied plus non-occupied receptors, after
displacement of the endogenous ligand with Mersalyl.
As the cellular composition of bone changes in aluminium
toxicity, modification of the ratio of receptor bearing to
nonreceptor bearing cells is likely. We therefore examined
receptor status in other tissues including both classical (intes-
tine, parathyroid) and non-classical (epidermis, Sertoli cells)
target organs for 1,25(OH)2D3 [5, 6]. These included both
proliferating tissues and postmitotic tissues. Endorgan respon-
siveness to 1 ,25(OH)2D3 was investigated by determining duo-
denal calcium transport in the Ussing chamber, a system
previously shown to be sensitive to changes in circulating
1 ,25(OH)2D3 in a variety of situations [7—9]. The fact that we
obtained data on both receptor status and functional response in
the same tissue, the intestine, enabled an assessment of the
relative functional significance of the simultaneous alterations
occuring in aluminium toxicity.
Methods
Animals
Male Wistar rats (Firma Ivanovas, Kisslegg/Allgau, FRG),
initial weight 309 18 g, were allowed free access to deionized
distilled water and standard Altromin C 1000 diet (Altromin
Co., Lage/Lippe, FRG) for a one week run—in period. The diet
contained 500 IU vitamin D3/kg, 0.95% in calcium, 0.65%
phosphorous (wet/wt). During the experimental periods, con-
trol animals with solvent injection and experimental animals
with aluminium chloride injection were pairfed. The animals
were kept in single cages with controlled room temperature
(22°C) and humidity (70%) with a 12 hr light on/12 hr light off
cycle. In one experiment, animals were offered ad libitum
Altromin C 1000 diet with 1.5% strontium (wet/wt) as Sr-Cl2 or
Altromin C 1000 as control, respectively, for 14 days.
Experimental protocol
In order to prepare aluminium chloride, an aqueous solution
of anhydrous Aid3 was prepared to yield a concentration of 2.7
g elemental aluminium per liter. An appropriate volume of this
solution was injected. With the use of random numbers, animals
were allocated to one of the three groups: control group (no
injections, fed ad libitum); solvent injection group (pairfed to Al
injection group) and aluminium (Al) injection group.
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Two different time—courses of aluminium intoxication were
studied. In a first protocol (in the following called short—term),
the total duration of the experiment was three weeks. Experi-
mental animals received daily an intraperitoneal injection of
AId3, the injected dose rising incrementally from 0.27 to 2.7
mg, yielding a total dose of 51 mg AId3 (11 mg elemental Al) per
animal. Control rats received intraperitoneal saline only.
In the 16 week experiments (in the following called
long—term), intraperitoneal injections were administered on five
days per week, the injected dose rising incrementally from 0.27
to 2.7 mg, yielding a total dose of 192 mg AId3 (41.4 mg
elemental Al) per animal. Control rats received intraperitoneal
saline only.
Animals were weighed once per week throughout the exper-
iment. Blood was taken on the first and last day of the
experiment by retroorbital puncture. At the end of the experi-
ment, animals were sacrificed under light ether anaesthesia by
neck dislocation. The following organs were removed quickly
and further prepared at 4°C in phosphate buffered saline:
intestine, testis, skin and bones (femora and tibia). In one series
of short—term Al exposure, parathyroid glands were removed
surgically at the end of the experiment with the use of an
operating microscope.
In a separate series, animals were given strontium diet (1.5%)
as strontium—chloride for 14 days to inhibit renal 1-a-hydrox-
ylase. Control animals were given standard Altromin 1000 diet.
For the intestinal Ca transport studies, rats received either
Aid3 i.p. or solvent according to the short—term protocol. Prior
to the flux determinations, groups of aluminium intoxicated and
control animals were given 50 ng 1 ,25(OH)2D3 per day (dis-
solved in 100 sg ethanol) by gavage for four days. Animals were
anesthetized with ether and duodenal segments were removed
prior to sacrifice by exsanguination.
Preparation of tissues for receptor binding studies
Epidermis. Shaved skin of the back was removed, immedi-
ately spread on filter paper and frozen to —80°C on a cold table
(Ultracryomat; Jahnke Co., Stauffen, FRG). The frozen epider-
mis was scraped off with a scalpel and collected in 4 volumes
(wt/vol) of TED (10 mrvt Tris HCI, 1.5 mM EDTA, 1 mM
dithiothreitol, 10 m sodium molybdate; pH 7.4, 4°C) and
homogenized with a Polytron homogenizer (Jahnke Co., Stauf-
fen/Breisgau, FRG) [101.
Intestinal mucosa. Intestinal mucosa was scraped off intes-
tine using glass slides [111 and homogenized in four volumes
(wtlvol) of homogenization buffer (TED) as described above.
Bone. From the femur and tibia epiphyseal cartilage was
carefully removed. The tubular bones were split lengthwise.
Marrow was removed by scraping and by flushing with ice—cold
saline. Bone tissue was then stored at —80°C. For the receptor
assay, bones were homogenized using a Polytron homogenizer
(Jahnke Co., Stauffen, FRG) in the TED homogenization buffer
at 0°C.
Parathyroid gland. Twenty parathyroid glands were har-
vested from 10 animals, put immediately into 4°C TED buffer
and homogenized as described above.
Sertoli cells. Sertoli cells were prepared as described previ-
ously [12] using a modified method according to Dorrington
[13]. Decapsulated testes were placed in Hepes buffer MEM (M
199) (0.2 M Hepes; 0.1% BSA; 0.01% penicillin; 0.02% strepto-
mycin; pH 7.4; 4°C; 95% 02, 5% C02) including 1 mg collagen-
ase (129 U) in 5 ml buffer. After 30 minute incubation (gentle
shaking 60 osc/min; 34°C; 95% 02, 5% C02) tubular fragments
were sedimented (5 mm, room temperature). Seminiferous
tubules were prepared from the washed (3 times) sediment and
layered on a 0 to 90% Percoll density gradient. Tubular frag-
ments were incubated (30 mm, 34°C, 95% 02, 5% C02; 10 ml M
199) with constant shaking (60 osc/min) using 10 mg collagen-
ase.
The pellet was filtered through polyester gauze (200 pm)
allowing spermatogonia and Sertoli cells to pass. After centrif-
ugation (2 mm, 800 g), the pellet (Sertoli cells) was washed (3 x;
M 199). Checks for viability and purity of preparation [10]
included cAMP response to FSH (sevenfold stimulation) but
not to HCG or LH; no NBT indicator reaction (excluding
contamination with Leydig cells) and exclusion of trypan blue
(final concentration 0.0 1%) by >95% of cells.
Analytical techniques
Preparation of nuclear extracts. The methods described
previously were used [12]. In brief, the above homogenates
were centrifuged (500 x g; 10 minutes; 4°C) to yield the nuclear
pellet. A crude chromatin fraction was prepared by resuspend-
ing the pellet three times in the above buffer with 0.5% Triton
X-l00 (pH 7.4) followed by centrifugation (10,000 g; 10 mm).
The resulting crude chromatin pellet was then extracted with
0.4 M KC1/TED (KTED) for 45 minutes with frequent mixing.
Chromatin extract was centrifuged (5,000 g!lO mm) and the
resulting supernatant was subsequently centrifuged at 100,000 g
for one hour.
Sucrose density gradient analysis. The method has been
described in detail elsewhere [10, 11]. In brief, a linear 5 to 20%
sucrose density gradient in TED buffer with 0.3 M KCI and 10
m sodium molybdate (4 ml) was made using a self—designed
gradient former. Nuclear samples (0.2 ml) were incubated for
two hours with I nM [3H] 1 ,25(OH)2D3 alone or after addition of
a 100-fold molar excess of l,25(OH)2D3; 25(OH)D3; 1-a(OH)D3,
24R,25(OH)2D3. They were then carefully layered on top of
pre-equilibrated (2 hr, 4°C) gradients and centrifuged (255,000 g;
21 hr; 4°C; SW6O rotor Beckman Instruments Co., Fullerton,
California, USA). Seven drop fractions were collected. The
sedimentation rate (in Svedberg units, S) for proteins was
estimated using ['4C]labeled ovalbumin (3.7 S) or bovine y-
globulin (7.3 5) as reference proteins.
Hydroxyapatite assay. Receptor—bound tritiated and non-
labeled vitamin D metabolites were assayed as described pre-
viously [10, 11]. Aliquots of 0.5 ml, 50% (wt/vol) hydroxyap-
atite buffer—slurry (4°C) was added to the fraction for a 15
minute incubation with frequent vortexing. The samples were
then centrifuged at 1000 x g for five minutes. The
hydroxyapatite pellets were washed three times with 1 ml buffer
0.5% Triton X100 (pH 7.4). The final washed pellet was
extracted for tritiated secosterols with ethanol. The dried
extracts were dissolved in counting solution (Aquasol NEN
Co.) and determined by liquid scintillation counting.
Saturation analysis. Saturation analysis was according to
Scatchard [141 Almquots of diluted nuclear extracts (0.1 ml/0.3
mg protein) were incubated with varying concentration (0.1 to 5
nM) of [3H] l,25(OH)2D3 in the absence (total binding) or
presence (non-specific binding) of a 100-fold molar excess of
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unlabeled l,25(OH)2D3 for 16 hours at 4°C. Bound [3H]
1 ,25(OH)2D3 was determined using the above hydroxyapatite
assay.
Binding of 1,25(OH)2D3 receptor to DNA cellulose. DNA
cellulose (0.3 mg DNA/ml) was prepared according to Alberts
and Herrick [15] using highly polymerized calf thymus DNA
(type I, Sigma R) and Whatman CF-il cellulose. Each column
was equilibrated in TED for 16 hours at 4°C prior to use, and
run at a flow rate of 5 mllhr/cm2. Samples were loaded onto the
columns, washed with three volumes of TED and eluted in 10
volumes with a linear gradient from 0.1 M to 0.6 M KC1 in TED.
Nuclear extracts (0.6 mi/i .8 mg protein) of cell fractions were
incubated for two hours at 4°C with [3H] 1 ,25(OH)2D3 prior to
chromatography on DNA cellulose.
Analysis of total specific binding after Mersalyl pretreatment
[16]. Unoccupied 1 ,25(OH)2D3 binding sites were determined
by measuring secosterol binding in nuclear preparations incu-
bated with 3 flM [3H] 1,25(OH)2D3 as described above. To
determine total 1 ,25(OH)2D3 specific binding activity, endoge-
nous ligand was first displaced by incubation of nuclear prepa-
rations in KTE buffer with Mersalyl at a final concentration of
1 m'i. After three hours, charcoal (2.5%)-Dextran (0.25%) was
added to remove endogenous secosterole and 3 mM dithiothrei-
to! to reduce the functional SH groups. Subsequently, the
nuclear fraction was incubated for 16 hours with 3 flM [3H]
l,25(OH)2D3 (± 300-fold molar excess of radioinert
i,25(OH)2D3) at 4°C. After the charcoal step, less than 3% of
activity was recovered in the nuclear fraction. As a control, an
aliquot was incubated without charcoal—Dextrane—extraction.
Serum analyses. Calcium, and serum alkaline phosphatase
were measured using a Technicon Autoanalyzer (Tarrytown,
New York, USA). Serum aluminium was determined using
flameless atomic absorption spectrophotometry (graphite fur-
nace; automatic delivery system) with a Perkin Elmer type 4030
(Norwalk, Connecticut, USA). Hemoglobin and MCV were
measured using Coulter Counter technique (Coulter Electron-
ics, Hileah, Florida, USA). Plasma l,25(OH)2D3 levels were
measured according to Scharla et al [17].
Ussing chamber experiments
Intestinal transmural calcium fluxes were determined using
the modified Ussing apparatus [7, 8]. Duodenal segments 10 cm
in length, immediately distal to the pylorus, were dissected. The
segments were then excised, opened along the mesenteric
border and mounted unstripped in the modified Ussing cham-
ber. Tissue apertures were 0.5 m2. The mounted intestinal
segment was bathed in a phosphate—free Krebs—Ringer bicar-
bonate solution maintained at pH 7.4 and 37°C (Nat 145, K4
4.7, Ca 1.25, Mg 1.2, C1 i27.2, HCO3 25, SO4 1.2,
D-glucose 11 mmol/liter). Each hemichamber compartment
contained 10 ml electrolyte solution and was aerated with 95%
02; 5% CO2 throughout the experiment. The solutions bathing
the mucosal and serosal sides were connected via agar bridges
to calomel electrodes for the direct measurement of the poten-
tial difference (PD) and to Ag-AgC1 electrodes for the passage of
direct current through the tissue, using an automatic voltage
clamp (Dual Voltage Clamp: 616C-3 Bioengineering, The Uni-
versity of Iowa). The short—circuit current (Isc) was recorded in
the absence of PD after appropriate corrections for the resist-
ance of the fluid between the two PD-sensing bridges. Conduc-
tance (U) was calculated from Isc and PD. Mucosa—to—serosa
(Jm-.s) and serosa—to—mucosa (J.m) fluxes were paired em-
ploying the 30% conductance matching criterion of Walling and
Kimberg [9], After the steady state had been reached (60 mm),
30 Ci 45Ca was added to either the serosal or the mucosal
side of the paired chambers. One ml samples were taken from
the "cold" side at 20 minute intervals for one hour. Each
aliquot removed was replaced with the same solution without
45Ca . Each aliquot removed was counted in 5 ml scintillation
fluid (Pico-Fluor TM 30, United Technologies, Packard Instru-
ment Company, Inc., Downers Grove, Illinois, USA) with a
LKB 1212 RackBeta Wallac Liquid Scintillation Counter. Cal-
cium fluxes were calculated as described by Schultz and
Zalusky [181 and expressed as nmol/cm2 x hr. Steady state
values were reached after 20 minutes and reported as the mean
of the fluxes in the two subsequent 20 minute periods. Net flux
was calculated on paired tissues from the same animal (Jnet=
Jm.s — Js—e.m).
Chemicals
1 ,25-Dihydroxy [26,26-methyl-3H] cholecalciferol (158 Ci/
mmol), 25-hydroxy [23,24-3H] cholecalciferol (85 Ci/mmol)
were obtained from AmershamlBuchler Co. (Braunschweig).
Radiochemical purity by HPLC was 93 to 98% with no other D
metabolites demonstrated. Radioinert chromatographically
pure l,25(OH)2D3, 25(OH)D3 and 24R,25(OH)2D3 was used
(Hoffmann—La Roche Co., Wyhl/FRG). Bovine serum albumin
[14C]methylated (20 CiImg protein); ovalbumin [14C]methyl-
ated (20 Ci/mg protein), 125j cAMP (150 Ci/mmol) and 45Ca (4
to 50 Ci/g Ca) were from NEN Company. Hydroxyapatite,
dithiothreitol, Triton X-100, Na-molybdate were from Sigma
(Munich). Hepes—buffered minimum essential medium (M 100),
fetal calf serum (FCS), collagenase (129 U/mg) were purchased
from Seromed Biochem KG (Berlin, FRG); HCG (5000 U/mg,
Primogynol') was purchased from Schering (Berlin, FRG);
NAD, dehydroepiandosterone, nitroblue—tetrazoliumchloride
(NBT) was from Serva (Heidelberg, FRG); FSH (75 lU/mg) was
purchased from Serono (Freiburg); and Mersalyl was from
Hoechst Co. (Frankfurt, FRG).
Results
Description of the model
As shown in Table 1, animals were well randomized with
respect to initial body weight. Despite the pairfeeding protocol,
weight gain was considerably less in animals with aluminium
loading, particularly in the long—term study. A highly significant
increase of serum aluminium was achieved, and this was
accompanied by microcytic anemia, indicated by low Hb and
low mean corpuscular volume. Serum calcium (P < 0.05) values
tended to be higher in Al-intoxicated rats of the short—term, but
not the long—term study. Circulating 1 ,25(OH)2D3 levels were
significantly decreased.
1 ,25(OH)2D3 binding studies
Four independent series of animals were examined using the
short—term protocol. The data were consistent and tables and
figures give the results of one representative experiment. The
study using the long—term protocol was carried out once.
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Table 1. Blood analyses and body weight
Short term (3 weeks) Long term (16 weeks)
Solvent injection Al loading Solvent injection Al loading
Serum Ca mg/dl 2.44 0.11 2.55 0.19° 2.55 0.11 2.51 0.1
Serum phosphorous mg/dl 7.53 0.69 8.06 0.79 9.03 0.4 7.93 0.4°
Alk. ph'ase U 243 37 259 61 292 70 269 52
Serum Al p.g/ml <0.001 0.191 0.03° <0.001 0.771 0.04°
Serum l,25(OH)2D3 pg/m/ 74.0 25 43.1 18.6 — —
Hb gIdi 15.8 3.7 13.3 4.3 14.8 0.4 12.9 o.6
mean corpuscular volumefi 63.2 6.1 56.3 3.la 66.8 1.48 56.2 2.3°
initial weight g 315 13 312 14 305 12 308 14
final weight g 385 17 365 13 516 20 460 22°
All values so; 10 animals per group.












Fig. 1. Sucrose density gradient sedimentation profile of the
1,25(OH)2D3 (1 nM, 3.5 5) receptor from epidermal keratinocytes of rats
with short—term Al-loading. Nuclear fraction in KTED buffer (pH 7.4;
4°C) was incubated for two hours at 4°C with vitamin D metabolites as
indicated and sedimented in linear 5 to 20% (wt/vol) sucrose
density—gradients by ultracentrifugation (255,000 x g for 21 hr at 4°C).
Incubation occurred with 1.5 nM [3H] I ,25(OH)2D3 in the absence
or presence (0—0) of a 100-fold molar excess of unlabeled
I ,25(OH)2D3. No obliteration of binding was observed (data not shown)
with 100-fold molar excess of 25(OH)D3; 24R,25(OH)2D3. Arrows:
['4C]ovalbumin at 3.7 5 and t'4C]bovine gammaglobulin at 7.3 S.
2.1. Epidermis. In this and the following experiments (Fig.
1—3), no significant differences were noted between untouched,
ad-libitum—fed control animals and solvent—injected pairfed
animals to the experimental group. Only the data for the latter
group will be reported.
As shown in Figure 1, sucrose density gradient—analysis of
specific [3H] 1 ,25(OH)2D3 binding by epidermal keratinocytes
semiquantitatively showed increased binding by a 3.5 S macro-
molecule in Al-loaded animals (short—term study) over solvent
controls. Similar data were obtained in the long—term study (not
shown).
As indicated by Figure 2, saturation analysis confirmed a 40%
increase of maximal binding capacity (Nniax) for epidermal
keratinocytes of Al-loaded animals both in the short—term and
long—term study. In both instances, no change of binding
affinity (K0) was observed. Preincubation of the nuclear frac-
tion of epidermis of control animals for three hours in vitro in
KTED buffer at 4°C with 30 M A1CI3 did not affect [3H]
1,25(OH)2D3 binding; Scatchard analysis showed unchanged
Nmax and KD. In this and the following, all Scatchard values
refer to the mean of five replicate measurements of the tissue
pool from 15 experimental animals.
To separately assess occupied and unoccupied receptors,
specific binding of [3H] 1 ,25(OH)2D3 was assessed in the
nuclear fraction of epidermal cells of Al (short—term) and
control animals at 3 flM, that is, approximately at the plateau of
saturation (compare Fig. 2). In control animals, total specific
binding after Mersalyl was 17.9 fmol/mg protein and without
Mersalyl 13.3 fmol/mg protein, that is, the proportion of unoc-
cupied receptors was 74%. In Al-treated animals, the respective
figures were 29.7 fmol/mg protein and 26.2 fmol/mg protein, that
is, the proportion of unoccupied receptors was 88% (repre-
sentative figures of one of three experiments). After 25 ng
l,25(OH)2D3/l0O g body wt two times daily i.p. over four days,
total specific binding with and without Mersalyl was 21.4
fmol/mg protein and 19.1 fmol/mg protein, respectively, in
Al-treated animals with l,25(OH)2D3 and 18.8 fmol/mg protein
and 14.5 fmol/mg protein, respectively, in control animals
treated with I ,25(OH)2D3.
In animals exposed for 14 days to 1.5% Sr diet, serum
l,25(OH)2D3 levels were lower (21.1 :t 8.4 pg/mI vs. 120 48 in
controls; N = 11 per group) and Nmax in the nuclear fraction of
the epidermis was increased (35 fmol/mg protein vs. 28 fmol/mg
protein in controls).
To further assess whether binding of 1 ,25(OFI)2D3 by epider-
mal cells complied with the known characteristics of the
1 ,25(OH)2D3 receptor, we examined binding of the secosterol
receptor complex to DNA, using affinity chromatography.
Presumed electrostatic interaction of the receptor with nuclear
DNA is reversed by increasing the ionic strength of the elution
buffer, elution occurring at 0.27 M KCI. As indicated in Figure
3, the prelabeled holoreceptor complex eluted at 0.27 M KCI.
Similar DNA affinity chromatography patterns were seen in
other tissues examined (intestine, Sertoli cells; data not shown).
Intestinal mucosa. Increased binding of [3Hjl,25(OH)2D3 by
a 3.5 S macromolecule was found by sucrose density gradient
analysis in intestinal mucosa of animals subjected to either
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Fig. 2. Saturation analysis of the binding of [3HJ1 ,25(OH)2D3 to the nuclear fraction of epidermal keratinocytes of rats with short—term and
long—term Al loading. Nuclear fraction in KTED (pH 7.4; 4°C) was incubated for 16 hr at 4°C at a final concentration of 2 to 4 mg protein/mi with
increasing concentrations (0.1 to 10 nmol) of [3H] 1 ,25(OH)2D3 in the presence or absence of a 100-fold molar excess of non-radioactive
1 ,25(OH)2D3. Bound and free I ,25(OH)2D- were separated with hydroxyapatite. The saturation plot showed a plateau at 2 nmol. Scatchard analysis
of specific binding yielded a straight regression curve (r = 0.9) indicating a single class of non-interacting binding sites. The equilibrium constant
KD calculated from the slope of the regression curve was 2.7—3.4 X l0M and the extrapolation of the curve to the abscissa yielded an Nmax of
19 fmoi/mg protein in the solvent control group. Each value represents the mean of 5 replicate measurements of a tissue pool from 15 experimental
animals.
Fig. 3. Elution of specific I ,25(OH)2D3 receptors from DNA cellulose
(affinity chromatography). Study of epidermal keratinocytes of rats.
The nuclear fraction (4 mg protein/mi) was preincubated with I nmoi
[3H]1 ,25(OH)2D3 alone (•—•) or with 100-fold molar excess of
unlabeled 1 ,25(OH)2D3 (O—O) and placed on 1.5 x 6 cm column of
DNA cellulose. After extensive washing of unabsorbed material, the
column was eluted in 10 volumes with a linear gradient between 0.1 to
0.6 M KCI (—). Aliquots (0.25 ml) of column fractions were counted
for [3H] 1 ,25(OH)2D3 to determine the distribution of the I ,25(OH)2D3
holoreceptor complex. A 100-fold molar excess completely obliterated
the radioactive peak at 0.27 M KC1. Binding of the [3H] I ,25(OH)2D3
holoreceptor complex to DNA points to a possible specific role of
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Fig. 4. Saturation analysis of the binding of[3HJ 1,25(OH)2D3 to the
nuclear fraction of whole bone homogenate. Experimental procedure
as in legend to Fig. 2.
concentration of 1 ,25(OH)2D3 (3 nM). Specific binding was 41.8
0.3 fmol/ntg protein in Al animals (short—term protocol) and
11.4 05 in controls.
Sertoli cells. Figure 5 shows increased maximal specific
binding capacity for 1 ,25(OH)2D3 in Sertoli cells of animals with
long—term exposure over that in solvent controls with no
change of binding affinity (KD). Again, similar findings were
obtained in the short—term study (not shown).
A synopsis of the results is given in Table 2, which indicates
a consistent and marked increase of maximal specific binding
capacity for all tissues examined. This was true for Al loaded
animals of the short—term and even more so of the long—term
series.
Intestlnal Ca transport studies (Ussing chamber)
As shown in Table 3, animals with short—term Al loading had
significantly lower Jms and tended to have lower Jnet than
control animals. Jms and Jflet increased significantly in response
fmol/mg protein vs. 24.6 2.3 in the short—term and 26.3 2.2
fmol/mg proteii vs. 19.1 2.1 in the long—term study: experi-
mental vs. control group). The equilibrium dissociation con-
stant KD was unchanged (2.4 0.3 vs. 3.0 0.5 X 10-10 M for
the short—term and 2.7 0.3 vs. 2.8 0.3 X 10b0 M for the
long—term study).
Bone. As shown in Figure 4, Scatchard analysis showed an
increase of Nmax in the nuclear fraction of whole bone
homogenate of Al-loaded animals (short—term protocol) versus
solvent injected controls with no change of KD. Similar findings
were obtained in the long—term study (data not shown).
Parathyroid glands. Because of limited availability of tissue,
[3H] 1 ,25(OH)2D3 binding could be examined only at one
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to 50 ng 1 ,25(OH)2D3/day post-operatively for four days in both
groups, but the increment of Jms and Jnet induced by
l,25(OH)2D3 was smaller in Al animals. Jms and Jnet were
significantly reduced in Al intoxicated animals administered
I ,25(OH)2D3 compared with control animals administered
l,25(OH)2D3. Pretreatment with l,25(OH)2D3 had no significant
effect on short circuit current (I) and conductivity (G).
Discussion
The present study documents that both modest and severe
aluminium loading of rats with normal renal function lowers
plasma 1 ,25(OH)2D3 levels and causes an increase of maximal
specific binding capacity for 1 ,25(OH)2D3 in various classical
(intestine, bone, parathyroids) and non-classical target tissues
of vitamin D3 (epidermis, Sertoli cells). Low circulating
l,25(OH)2D3 concentrations were associated with, but not
necessarily causally related to, reduced 'ms for calcium in the
duodenum. These animals also manifested an impaired intesti-
nal response to exogenous l,25(OH)2D3. Such data are consist-
ent with the hypothesis that in aluminium toxicity, responsive-
ness to 1 ,25(OH)2D3 is reduced by a mechanism which is
post-receptor in nature.
Several methodological problems deserve comment. In
aluminium intoxicated animals [191 the relative proportion of
different bone cells may change. Studies of other authors [20]
and of our laboratory [211 indicate that osteoblasts and/or
osteocytes, but not osteoclasts, express 1,25(OH)2D3 receptors.
The relative abundance of osteoblasts and osteoclasts in our
model is unknown. Similar interpretational problems arise with
other tissues, such as epidermis [10]. Increased binding capac-
ity in replicating tissues can either indicate increased number of
receptors per cell or increased proportion of receptor—bearing
cells. To circumvent this problem, Sertoli cells as postmitotic
tissue—at least under the conditions of the experiment—were
chosen. Since a similar increase of maximal specific binding
capacity was found, the most likely explanation is an increase
of receptors per target cell.
1 ,25(OH)2D3 concentrations were diminished as previously
found in Al intoxicated animals [221 and man [23], but (at least
in chicken) Al does not directly inhibit renal l-a-hydroxylase
[24]. It is unlikely that the —30% increase of unoccupied
I ,25(OH)2D receptor binding capacity is explained by changes
in receptor occupancy, since at normal serum concentrations of
I ,25(OH)2D3 only few percent of receptors are occupied [25].
This assumption is borne out by direct measurements of binding
capacity under conditions where the endogenous ligand was
dissociated prior to the binding experiments [16].
Various transition elements stabilize steroid receptors in
vitro [25]. An effect of Al on receptor stability is unlikely,
however, in view of the negative results of our in vitro exper-
iments with concentrations of Al in the micromolar range.
Previous studies have found biphasic actions of Al on
osteoblasts in vitro [26, 271. Therefore, we examined two
different levels of Al intoxication, using doses comparable to
those of previous investigators [19, 28—31]. The consistent
increase of I ,25(OH)2D3 binding in all tissues irrespective of
duration and degree of Al loading suggests that 1,25(OH)2D3
receptor changes are sensitive to even modest Al doses and are
not sensitive to possible differences of aluminium partitioning
into the various tissues [28].
The mechanism of I ,25(OH)2D3 receptor changes remains
undefined. It is of note that similar changes were observed with
strontium feeding which causes lowering of circulating
1 ,25(OH)2D3 levels and a reciprocal increase of 1 ,25(OH)2D3
receptors. Whether the similar directional changes in Al intox-
ication represent receptor up—regulation requires further study.
Duodenal calcium transport was investigated to assess the
functional significance of increased receptor expression in a
classical target organ for 1 ,25(OH)2D3. Both in our hands [71
and those of others [32] duodenal calcium transport in the
modified Ussing chamber has been shown to reflect the level of
circulating 1 ,25(OH)2D3 in a variety of pathophysiologic situa-
tions.
In a similar fashion, in the present study a parallel reduction
in baseline net calcium flux (Jnet) mucosa—to—serosa calcium
flux (Jms) and serum 1,25(OH)2D3 was observed in aluminium
intoxicated animals. The finding is consistent with the 17%
reduction in baseline intestinal calcium absorption reported
recently by Henry and Norman [24] in the aluminium intoxi-
cated chick. Although the latter difference did not reach statis-
tical significance, both their findings and ours suggest that there
is no direct relationship between receptor number and endorgan
function. With respect to the response of aluminium intoxicated
animals to exogenous l,25(OH)2D3, it is noteworthy that not
only were the absolute levels to which JmS and Jnet rose
diminished compared to those of control animals, but also that
the incremental response to 1 ,25(OH)2D3 was blunted: A J for
aluminium intoxicated animals being 63% of A Jnetfor controls.
The increased receptor expression indicates the post-receptor
nature of the pathogenetic mechanism, and the similarly
blunted response to 1 ,25(OH)2D3 in terms of both intestinal
calcium transport and of calcium binding protein, observed by
Henry and Norman [24], supports this contention. These au-
thors also reported aluminium intoxication (5 mg/kg/day for 5
days) to be consistently associated with increased bone
calcium—mobilization in their model [24]. Our observations
further suggest that the tendency to hypercalcemia frequently
observed in aluminium intoxicated subjects treated with vita-
min D metabolites [32] is presumably not primarily due to
Solvent injection Al-loading (16 weeks)
= 45 fmollmg protein
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Fig. 5. Saturation analysis of the binding of [3HJ I ,25(OH)2D3 to the
nuclear fraction of isolated Sertoli cells of the testes of rats with
long—term A/loading. Experimental procedure as in legend to Fig. 2.
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Table 2. Number (Nmax) of unoccupied I ,25(OH)2D3 receptors (Scatchard analysis) in aluminium loaded rats compared with solvent controls
(all data in fmol bound/mg protein; in brackets as percent of control value)
Short term (3 weeks) Long term (16 weeks)
Solvent injection Al loading Solvent injection Al loading
Epidermal keratinocytes 19.2 2.1 26.3 2.la 19.5 1.8 29.3 2.la
(136%) (150%)
Intestinal mucosa 24,6 2.7 32.4 2.9a 19.1 2.1 26.3 2.2
(131%) (137%)
Bone 15.0 2.3 23.1 2.7 19.0 1.3 34.1 3.0
(153%) (179%)
Sertoli cells 22.3 1.8 29.4 2.Oa 25.1 1.3 44.8 3.2a
(131%) (179%)
All values SD, 15 animals per group
a Significant differences (P < 0.01) between control and experimental group (Wilcoxon test)
Table 3. Intestinal Ca transport in Al intoxicated rats (short—term protocol) with or without pretreatment with 1 ,25(OH)2D3
(50 ngld for 4 days)
Jms J,m .j,, I,, Ionized serumG calcium
nmol/cm2 x hr uA/cm2 mS/cm2 mmol/liter
Al loading (6) 29.1 3.2' 25.1 3.5 4.0 4.4 130 10,0 22.4 1.5 1.39 0.02
control (6) 41.1 4.2 33.2 2.5 8.2 33a 114 9.6 22.9 1.6 1.32 0.01
Al loading + 1 ,25(OH)2D3
(9) 53,7 52c,d 27.7 3.8 26.0 55ac.e 104 9.0 21.9 0.7 1.52 0.10
control + l,25(OH2D3 (9) 71.0 5.3" 27.9 3.0 43.1 5.7 116 10.1 21.3 1.7 1.53 0.04
All values SEM, Mann-Whitney U test for all comparisons except Jms V5. Jm for which the Wilcoxon matched pairs, signed ranks test was
used, both tests two tailed.
a Jms vs. Jsm (J, different from zero), P < 0.05b Al vs. control, P < 0.05
Al + 1,25 vs. control + 1,25, P < 0.05
d Al + 1,25 ys. Al, control + 1,25 vs. control, P < 0.005
a Al + 1,25 vs. Al, control + 1,25 vs. control, P < 0.03
increased intestinal absorption of calcium but more probably
dependent on abnormalities of bone function.
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